AVI BioPharma Receives Orphan Drug Designation For AVI-4658 For Treatment Of Duchenne Muscular Dystrophy

AVI BioPharma, Inc. (Nasdaq:AVII), announced that the U.S. Food and Drug Administration’s (FDA) Office of Orphan Products Development has granted orphan drug designation to AVI-4658 for the treatment of Duchenne muscular dystrophy (DMD). AVI-4658 uses AVI’s ESPRIT technology (Exon Skipping Pre-RNA Interference Technology) and is designed to benefit patients with certain mutations in the dystrophin gene. [click link for full article]

More: continued here

Filed under: Muscular Dystrophy on November 7th, 2007